Molecular Characteristics of Diffuse Large B-cell Lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) Trial: Correlation with Interim PET and Outcome

Overview

Journal Blood Cancer J

Date 2019 Aug 21

PMID 31427567

Citations 5

Authors

Julia Richter

Andreas Huttmann

Jan Rekowski

Christine Schmitz

Selina Gartner

Andreas Rosenwald

Martin-Leo Hansmann

Sylvia Hartmann

Peter Moller

Hans-Heinrich Wacker

Alfred Feller

Christoph Thorns

Stefan Muller

Ulrich Duhrsen

Wolfram Klapper

Affiliations

Soon will be listed here.

Citing Articles

Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphoma.

Johansson P, Alig S, Richter J, Hanoun C, Rekowski J, Durig J Ann Hematol. 2023; 102(12):3445-3455.

PMID: 37566280 PMC: 10640472. DOI: 10.1007/s00277-023-05393-1.

Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial.

Broecker-Preuss M, Becher-Boveleth N, Muller S, Huttmann A, Hanoun C, Grafe H J Cancer Res Clin Oncol. 2021; 148(10):2611-2621.

PMID: 34708297 PMC: 9470686. DOI: 10.1007/s00432-021-03796-z.

FDG-PET/CT in Lymphoma: Where Do We Go Now?.

Al Tabaa Y, Bailly C, Kanoun S Cancers (Basel). 2021; 13(20).

PMID: 34680370 PMC: 8533807. DOI: 10.3390/cancers13205222.

Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements.

Eertink J, Arens A, Huijbregts J, Celik F, de Keizer B, Stroobants S Eur J Nucl Med Mol Imaging. 2021; 49(3):943-952.

PMID: 34476551 PMC: 8803795. DOI: 10.1007/s00259-021-05498-7.

Antigen-agnostic microfluidics-based circulating tumor cell enrichment and downstream molecular characterization.

Cohen E, Jayachandran G, Hardy M, Venkata Subramanian A, Meng X, Reuben J PLoS One. 2020; 15(10):e0241123.

PMID: 33095819 PMC: 7584183. DOI: 10.1371/journal.pone.0241123.

References

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

Cunningham D, Hawkes E, Jack A, Qian W, Smith P, Mouncey P . Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013; 381(9880):1817-26. DOI: 10.1016/S0140-6736(13)60313-X. View

Cottereau A, Lanic H, Mareschal S, Meignan M, Vera P, Tilly H . Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2016; 22(15):3801-9. DOI: 10.1158/1078-0432.CCR-15-2825. View

Schmitz R, Wright G, Huang D, Johnson C, Phelan J, Wang J . Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. PMC: 6010183. DOI: 10.1056/NEJMoa1801445. View

Duhrsen U, Muller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R . Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2018; 36(20):2024-2034. DOI: 10.1200/JCO.2017.76.8093. View

Lin C, Itti E, Haioun C, Petegnief Y, Luciani A, Dupuis J . Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007; 48(10):1626-32. DOI: 10.2967/jnumed.107.042093. View

Copie-Bergman C, Cuilliere-Dartigues P, Baia M, Briere J, Delarue R, Canioni D . MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015; 126(22):2466-74. DOI: 10.1182/blood-2015-05-647602. View

Horn H, Ziepert M, Wartenberg M, Staiger A, Barth T, Bernd H . Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia. 2015; 29(7):1564-70. DOI: 10.1038/leu.2015.43. View

Yuan L, Kreissl M, Su L, Wu Z, Hacker M, Liu J . Prognostic analysis of interim F-FDG PET/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy. Eur J Nucl Med Mol Imaging. 2018; 46(2):478-488. PMC: 6333726. DOI: 10.1007/s00259-018-4198-6. View

10.

Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View